Literature DB >> 8270600

Suppressed cellular immunity in patients with nasopharyngeal carcinoma.

M Tsukuda1, S Sawaki, S Yanoma.   

Abstract

The subsets and functions of lymphocytes were investigated in patients with nasopharyngeal carcinoma (NPC). The patients were divided into two groups comprising tumor-bearing patients and those in remission. There was no difference in the proportion of T cells among tumor-bearing, remission and healthy control groups. The percentages of inducer/helper T cells and natural killer cells were smaller in the tumor-bearing group than in the control group whereas the percentage of suppressor T cells was greater in the tumor-bearing group. Phytohemagglutinin-stimulated blastogenesis was markedly suppressed in the tumor-bearing group. The responsiveness to interleukin-2 of blastogenesis and of natural killer and lymphokine-activated killer activities was lowered in the tumor-bearing group. These parameters in the remission group were intermediate between those of the tumor-bearing and control groups. These results suggest that cellular immunity is suppressed in patients with NPC and that the suppressed condition still remains even in remission. Immunotherapy is considered to be indispensable for the proper treatment of NPC.

Entities:  

Mesh:

Year:  1993        PMID: 8270600     DOI: 10.1007/bf01200735

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  13 in total

1.  Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma.

Authors:  Y T Foong; H M Cheng; C K Sam; J Dillner; W Hinderer; U Prasad
Journal:  Int J Cancer       Date:  1990-06-15       Impact factor: 7.396

2.  Lymphocyte subpopulations and mitogenic responses in nasopharyngeal carcinoma, prior to and after radiotherapy.

Authors:  J P Lamelin; R Ellouz; G De Thé; J P Revillard
Journal:  Int J Cancer       Date:  1977-11-15       Impact factor: 7.396

3.  Presence of in vivo-activated T-cells expressing HLA-DR molecules and IL-2 receptors in peripheral blood of patients with nasopharyngeal carcinoma.

Authors:  M Lakhdar; R Ellouz; H Kammoun; S Ben H'Tira; N Khedhiri; R Kastally; W H Fridman
Journal:  Int J Cancer       Date:  1987-06-15       Impact factor: 7.396

4.  Cellular origins of co-stimulator (IL2) and its activity in cytotoxic T lymphocyte responses.

Authors:  J Shaw; B Caplan; V Paetkau; L M Pilarski; T L Delovitch; I F McKenzie
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

5.  Light scatter as an adjunct to cellular immunofluorescence in flow cytometric systems.

Authors:  W P Hansen; R A Hoffman; S H Ip; K W Healey
Journal:  J Clin Immunol       Date:  1982-07       Impact factor: 8.317

6.  A comprehensive immunological analysis in chronic fatigue syndrome.

Authors:  S Gupta; B Vayuvegula
Journal:  Scand J Immunol       Date:  1991-03       Impact factor: 3.487

7.  Imbalance in T cell subsets in human diseases.

Authors:  M A Bach; J F Bach
Journal:  Int J Immunopharmacol       Date:  1981

8.  Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer.

Authors:  S P Schantz; N G Ordonez
Journal:  Nat Immun Cell Growth Regul       Date:  1991

9.  Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome.

Authors:  A Linde; B Andersson; S B Svenson; H Ahrne; M Carlsson; P Forsberg; H Hugo; A Karstorp; R Lenkei; A Lindwall
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

10.  Cellular origin of interleukin 2 (IL 2) in man: evidence for stimulus-restricted IL 2 production by T4+ and T8+ T lymphocytes.

Authors:  S C Meuer; R E Hussey; A C Penta; K A Fitzgerald; B M Stadler; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

View more
  6 in total

1.  Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma.

Authors:  Jiang Li; Zhou-Feng Huang; Geng Xiong; Hao-Yuan Mo; Fang Qiu; Hai-Qiang Mai; Qiu-Yan Chen; Jia He; Shu-Peng Chen; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2011-11-04       Impact factor: 5.531

2.  Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9.

Authors:  Cécile Keryer-Bibens; Catherine Pioche-Durieu; Cécile Villemant; Sylvie Souquère; Nozomu Nishi; Mitsuomi Hirashima; Jaap Middeldorp; Pierre Busson
Journal:  BMC Cancer       Date:  2006-12-08       Impact factor: 4.430

3.  High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.

Authors:  Laura Caggiari; Massimo Guidoboni; Emanuela Vaccher; Luigi Barzan; Giovanni Franchin; Annunziata Gloghini; Debora Martorelli; Paola Zancai; Maria Teresa Bortolin; Mario Mazzucato; Diego Serraino; Antonino Carbone; Paolo De Paoli; Riccardo Dolcetti
Journal:  Infect Agent Cancer       Date:  2007-03-01       Impact factor: 2.965

4.  Unusual coexistence of extramedullary plasmacytoma and nasopharyngeal carcinoma in nasopharynx.

Authors:  Ri-Chang Du; Hai-Nan Li; Wei Huang; Xiao-Ying Tian; Zhi Li
Journal:  Diagn Pathol       Date:  2015-09-17       Impact factor: 2.644

5.  Cytokine and immunoglobulin production by PWM-stimulated peripheral and tumor-infiltrating lymphocytes of undifferentiated nasopharyngeal carcinoma (NPC) patients.

Authors:  Lilia Fliss-Jaber; Radhia Houissa-Kastally; Kamel Bouzouita; Naceur Khediri; Ridha Khelifa
Journal:  BMC Cancer       Date:  2004-09-27       Impact factor: 4.430

Review 6.  Tumor-primed NK cells: waiting for the green light.

Authors:  May Sabry; Mark W Lowdell
Journal:  Front Immunol       Date:  2013-11-25       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.